ƾ¾Ý¡¶¹ã¶«Ê¡¿Æѧ¼¼ÊõÌü¹ØÓÚ2024Äê¶È¹ã¶«Ê¡¿Æѧ¼¼Êõ½±ÌáÃûÊÂÇéµÄ֪ͨ¡·£¨ÔÁ¿Æº¯Çø×Ö¡²2024¡³1564ºÅ£©ÒªÇó£¬ÏÖ½«ÎÒµ¥Î»¼ÓÈë2024Äê¶È¹ã¶«Ê¡¿Æѧ¼¼Êõ½±ÌáÃûÏîÄ¿ÓйØÄÚÈݽøÐй«Ê¾£¬Ïê¼û¸½¼þ¡£ ¹«Ê¾Ê±¼ä£º2024Äê12ÔÂ27ÈÕÖÁ2025Äê1ÔÂ2ÈÕ£¬¹²7ÈÕ¡£ ¹«Ê¾Æڼ䣬Èç¶Ô¹«Ê¾ÄÚÈÝÓÐÒìÒ飬ÇëÒÔÊéÃæÐÎʽÏòÁªÏµÈË·´Ó¦¡£ÒÔ¸öÈËÃûÒå·´Ó¦Çé¿öµÄ£¬ÇëÌṩÕæʵÐÕÃû£¨²¢Ç©Ãû£©¡¢ÁªÏµ·½·¨ºÍ·´Ó¦ÊÂÏîµÄÖ¤Ã÷ÖÊÁϵȣ»ÒÔµ¥Î»ÃûÒå·´Ó¦Çé¿öµÄ£¬ÇëÌṩµ¥Î»Ãû³Æ£¨²¢¼Ó¸Ç¹«Õ£©¡¢ÁªÏµÈË¡¢ÁªÏµ·½·¨ºÍ·´Ó¦ÊÂÏîµÄÖ¤Ã÷ÖÊÁϵȡ£·²ÄäÃûÒìÒé¡¢Áè¼ÝÆÚÏÞÒìÒéµÄ²»ÓèÊÜÀí¡£ ÁªÏµÈË£ºÁõ±ÌºÃ ÁªÏµµç»°£º15876588034 °ì¹«ËùÔÚ£º¹ãÖÝÊÐÌìºÓÇøÍò¿ÆÔÆA¶°7Â¥ ¸½¼þ£º2024Äê¶È¹ã¶«Ê¡¿Æѧ¼¼Êõ½±¹«Ê¾±í ÍþÁ®Ï£¶ûwilliamhill2024Äê12ÔÂ27ÈÕ 2024Äê¶È¹ã¶«Ê¡¿Æѧ¼¼Êõ½±¹«Ê¾±í£¨×ÔÈ»¿Æѧ½±¡¢¼¼Êõ·¢Ã÷½±¡¢¿Æ¼¼½ø²½½±¡¢¿Æ¼¼½á¹ûÍƹ㽱»¨Ñù£© ѧ¿Æ¡¢×¨ÒµÆÀÉó×éÖÐÒ½ÓëÖÐҩѧרҵÆÀÉó×éÏîÄ¿Ãû³Æ»ùÓÚ“Ö¤ÐÍ-°Ð±ê-ÁÆЧ”µÄÖÐÒ½¾·½ÂýÐÔÉöÔಡÑо¿Ìåϵ¹¹½¨¼°Ó¦ÓÃÌáÃûÕ߹㶫ʡÖÐÒ½Ò©¾ÖÖ÷ÒªÍê³Éµ¥Î»¹ãÖÝÖÐÒ½Ò©´óѧɽ¶«´óѧÖ÷ÒªÍê³ÉÈË£¨Ö°³Æ¡¢Íê³Éµ¥Î»¡¢ÊÂÇ鵥룩1. ÖܾÁÑþ£¨½ÌÊÚ¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ¡¢Ö÷ҪТ¾´£ºÏîÄ¿×ÜÂôÁ¦ÈË£¬Öƶ¨×ÜÌåÑо¿Ë¼Â·ºÍ¼Æ»®£¬Í³³ï¿ÎÌâÉè¼ÆÓëʵʩ£©2. Ëï½ðÅô£¨Ñо¿Ô±¡¢Íê³Éµ¥Î»£ºÉ½¶«´óѧ¡¢ÊÂÇ鵥λ£ºÉ½¶«´óѧ¡¢Ö÷ҪТ¾´£ºÂôÁ¦GPCRɸѡ¼¼Êõƽ̨µÄ´î½¨ÓëÓ¦Óü°½á¹ûת»¯Íƹ㣩3. Îâ¿¡±ê£¨Ö÷ÈÎÖÐҩʦ¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ¡¢Ö÷ҪТ¾´£ºÂôÁ¦ÉöÔ༲²¡»úÖÆÑо¿¼°½á¹ûת»¯Íƹ㣩4. Ñî·«£¨Ñо¿Ô±¡¢Íê³Éµ¥Î»£ºÉ½¶«´óѧ¡¢ÊÂÇ鵥λ£ºÉ½¶«´óѧ¡¢Ö÷ҪТ¾´£ºÂôÁ¦GPCRÖÐÒ½Ò©µÄɸѡ¼°½á¹ûת»¯Íƹ㣩5. Áº´ºÁᣨ¸±Ñо¿Ô±¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ¡¢Ö÷ҪТ¾´£ºÂôÁ¦ÎÂÑôÀûË®ÖÎÁÆÂýÐÔÉöÔಡµÄÁÆЧÆÀ¼Û£©6. ÖÜÔ°£¨½ÌÊÚ¡¢Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ¡¢ÊÂÇ鵥λ£º¹ãÖÝÖÐÒ½Ò©´óѧ¡¢Ö÷ҪТ¾´£ºÂôÁ¦ÕæÎäÌÀ¼°ÆäÓÐЧÉí·ÖÖÎÁÆÂýÐÔÉöÔಡµÄÁÆЧºÍ»úÖÆÑо¿£©7. ¹ùè´è´£¨Ñо¿Ô±¡¢Íê³Éµ¥Î»£ºÉ½¶«´óѧ¡¢ÊÂÇ鵥λ£ºÉ½¶«´óѧ¡¢Ö÷ҪТ¾´£ºGPCRÖÐÒ½Ò©µÄɸѡÓë¼ø¶¨ÒÔ¼°GPCR°Ð±êÓëÉöÔ༲²¡µÄ¹ØÁªÆÊÎö£©8. Áõ±ÌºÃ£¨ÎÞ£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£ºÍþÁ®Ï£¶ûwilliamhill¡¢Ö÷ҪТ¾´£ºÂôÁ¦ÂýÐÔÉöÔಡ»úÖÆÓëÒ©Îï×÷ÓÃÑо¿¼°½á¹ûת»¯Íƹ㣩9. ³Â¿¡÷裨Ö÷¹ÜÖÐҩʦ£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£ºÉîÛÚÊÐÖÐÒ½Ôº¡¢Ö÷ҪТ¾´£ºÂôÁ¦GPCR°Ð±êÔÚÂýÐÔÉöÔಡÖе÷¿Ø»úÖÆÑо¿£©10. ԬʥÁÁ£¨Ö÷¹Üҩʦ£¬Íê³Éµ¥Î»£º¹ãÖÝÖÐÒ½Ò©´óѧ£¬ÊÂÇ鵥λ£º¸ßÖÝÊÐÈËÃñÒ½Ôº¡¢Ö÷ҪТ¾´£ºÂôÁ¦ÖÐÒ½¾·½µÄҩЧÎïÖÊ»ù´¡Ñо¿£©´ú±íÐÔÂÛÎÄרÖøĿ¼ÂÛÎÄ1£º<Ãû³Æ: Structure of GPR101–Gs enables identification of ligands with rejuvenating potential¡¢ÆÚ¿¯£ºNature chemical biology¡¢Äê¾í£º2024,20¡¢Ðû²¼ÈÕÆÚ£º2024.4¡¢µÚÒ»×÷ÕߣºZhao Yang¡¢Í¨Ñ¶×÷ÕߣºJin-Peng Sun>ÂÛÎÄ2£º<Ãû³Æ: Zhen-wu-tang ameliorates membranous nephropathy rats through inhibiting NF-κB pathway and NLRP3 inflammasome¡¢ÆÚ¿¯£ºPhytomedicine¡¢2019,59¡¢Ðû²¼ÈÕÆÚ£º2019.4.2¡¢µÚÒ»×÷ÕߣºLiu Bihao¡¢Í¨Ñ¶×÷ÕߣºZhou Jiuyao >ÂÛÎÄ3£º<Ãû³Æ: Zhen-wu-tang protects against podocyte injury in rats with IgA nephropathy via PPARγ/NF-κB pathway¡¢ÆÚ¿¯£ºBiomedicine pharmacotherapy¡¢Äê¾í£º2018, 101¡¢Ðû²¼ÈÕÆÚ£º2018.5.22¡¢µÚÒ»×÷ÕߣºLiu Bihao¡¢Í¨Ñ¶×÷ÕߣºZhou Jiuyao >ÂÛÎÄ4£º<Ãû³Æ: Integrated Fecal Microbiome and Serum Metabolomics Analysis Reveals Abnormal Changes in Rats with Immunoglobulin A Nephropathy and the Intervention Effect of Zhen Wu Tang¡¢ÆÚ¿¯£ºFrontiers in Pharmacology¡¢Äê¾í£º2021, PMID: 33584283¡¢Ðû²¼ÈÕÆÚ£º2021.1.27¡¢µÚÒ»×÷ÕߣºLi Jicheng¡¢Í¨Ñ¶×÷ÕߣºZhou Jiuyao>ÂÛÎÄ5£º<Ãû³Æ: Paeoniflorin suppresses kidney inflammation by regulating macrophage polarization via KLF4-mediated mitophagy¡¢ÆÚ¿¯£ºPhytomedicine¡¢Äê¾í£º2023, 116¡¢Ðû²¼ÈÕÆÚ£º2023.5.24¡¢µÚÒ»×÷ÕߣºYiwen Cao¡¢Í¨Ñ¶×÷ÕߣºZhou Jiuyao>֪ʶ²úȨÃû³ÆרÀû 1£º <ÇÊ°±´¼1Á×Ëá4ÊÜ Ì弤¶¯¼Á ¼°ÆäÓëÕæÎäÌÀÁªºÏÔÚÖƱ¸ÖÎÁÆÂýÐÔÉöСÇòÉöÑ×Ò©ÎïÖеÄÓ¦ÓÃ>£¨ZL 202110678602. 2£¬ÖܾÁÑþ¡¢³Â¿¡÷è¡¢ÖÜÔ°¡¢Ëï½ðÅô¡¢Â¬ÈðÈðÎâãëçì¡¢¹ãÖÝÖÐÒ½Ò©´óѧ£¨¹ãÖÝÖÐÒ½Ò©Ñо¿Ôº£©£©
2024-12-27ÔÁ¹«Íø°²±¸ 44011202001884ºÅ
ÔÁ¹«Íø°²±¸ 44011202001884ºÅ